曲妥珠单抗新辅助化疗治疗HER-2阳性乳腺癌中体重指数与病理完全缓解的关系

Correlation between body mass index and pathological complete remission in HER2-positive breast cancer patients treated with trastuzumab neoadjuvant chemotherapy

谢炉峰 ¹缪继东 ¹蒋朝阳 ²李家伟 ¹冯江³

扫码查看

作者信息

1. 643000 四川省自贡市第四人民医院肿瘤科
2. 西部战区总医院放射治疗科
3. 643000 四川省自贡市第四人民医院妇产科
折叠

摘要

目的分析体重指数(BMI)与人表皮生长因子受体2(HER-2)阳性乳腺癌曲妥珠单抗新辅助化疗病理完全缓解(pCR)的关系.方法收集2018年5月至2022年6月曲妥珠单抗新辅助治疗HER-2阳性乳腺癌患者136例临床资料,分析不同BMI的HER-2阳性乳腺癌临床病理特征,采用单因素及多因素Logistic分析BMI与pCR的关系.结果 136例HER-2阳性乳腺癌患者中,获得pCR 43例(31.62％).BMI≥24组T分期(Ⅲ-Ⅳ期)、孕激素受体(PR)(阳性)、细胞核增殖抗原(Ki-67)(≥14)、淋巴结转移(阳性)高于BMI＜24组(P＜0.05).pCR组与非pCR组年龄、月经状态、Ki-67比较(P＞0.05);pCR组T分期(Ⅲ～Ⅳ期)、ER(阴性)、PR(阴性)、淋巴结转移(阳性)、BMI(≥24)低于非pCR组(P＜0.05).孕激素受体(PR)、淋巴结转移、BMI是影响ER-2阳性乳腺癌pCR的危险因素(P＜0.05).结论曲妥珠单抗新辅助化疗治疗HER-2阳性乳腺癌pCR与PR、淋巴结转移、BMI明显相关,结合BMI与HER-2阳性乳腺癌临床病理特征的关系,BMI是HER-2阳性乳腺癌曲妥珠单抗新辅助化疗pCR的独立危险因素.

Abstract

Objective To analyze the correlation between body mass index(BMI)and pathological complete remission(pCR)in human epidermal growth factor receptor 2(HER2)-positive breast cancer patients treated with trastuzumab neoadjuvant chemotherapy.Methods The clinical data of 136 HER2-positive breast cancer patients treated with trastuzumab neoadjuvant chemotherapy from May 2018 to June 2022 were collected.Clinical pathological features of them with varying BMIs were analyzed,and the correlation between BMI and pathological features of HER2-positive breast cancer patients treated with trastuzumab neoadjuvant chemotherapy was identified.Univariate and multivariate logistic regression analyses were performed to identify the correlation between BMI and pCR.Results Among 136 HER-2 positive breast cancer patients,43(31.62％)achieved pCR.The proportions of patients with T staging Ⅲ-Ⅳ,positive progesterone receptor(PR),Ki-67 ≥14,and positive lymph node metastasis in BMI≥24 group were significantly higher than those of BMI＜24 group(P＜0.05).There were no significant differences in the age,menstrual status and Ki-67 level between pCR group and non-pCR group(P＞0.05).The proportions of T staging Ⅲ-Ⅳ,negative estrogen receptor(ER),negative PR,positive lymph node metastasis,and BMI≥24kg/m2 in pCR group were significantly lower than those of no-pCR group(P＜0.05).PR,lymph node metastasis and BMI were the risk factors of pCR in HER-2 positive breast cancer(P＜0.05).Conclusion pCR is correlated with PR,lymph node metastasis and BMI in HER-2 positive breast cancer treated with Trastuzumab neoadjuvant chemotherapy.Concerning the relationship between BMI and clinicopathological features of HER-2 positive breast cancer,BMI is an independent risk factor of pCR in HER-2-positive breast cancer with trastuzumab neoadjuvant chemotherapy.

关键词

HER-2阳性乳腺癌/曲妥珠单抗/新辅助化疗/体重指数/病理完全缓解

Key words

HER-2 positive breast cancer/trastuzumab/neoadjuvant chemotherapy/body mass index/pathological complete remission

引用本文复制引用

基金项目

四川省卫生健康委员会医学科技项目(21PJ068)

出版年

2024

河北医药

河北省医学情报研究所

河北医药

CSTPCD

影响因子：1.075

ISSN：1002-7386

参考文献量16

段落导航